Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer

David Cella, David T Eton, Thomas A. Hensing, Gregory A. Masters, Bhash Parasuraman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PURPOSE: Our objective was to identify which symptoms of advanced lung cancer are most likely to change with objective tumor measurements (progressions and responses) or changes in performance status (PS). PATIENTS AND METHODS: Eighty patients with advanced non-small-cell lung cancer were studied during the first 12 weeks of chemotherapy. Symptoms were assessed weekly through telephone administration of the Functional Assessment of Cancer Therapy-Lung Symptom lndex-12. Data on PS were collected from patients every 3 weeks. Symptom reports were mapped onto clinical events (progression or response as determined by clinicians) and PS assessments. RESULTS: Disease progression and declining PS were associated with worsening of several symptoms. Pain, shortness of breath, cough, weight loss, and appetite loss worsened most from before to after progression. Patients with an objective response to chemotherapy reported more fatigue and difficulty breathing at response than before response. However, unlike patients who experienced progression, patients responding to chemotherapy never or rarely complained of clinically significant pain, weight loss, cough, chest tightness, nausea, or confusion before, during, or after response. With the exception of bother with side effects of treatment, confusion, and difficulty breathing, symptoms tracked fairly closely over the 12 weeks with changes in PS. Declining PS was associated with considerably more symptom worsening than unchanged or improved PS, independent of treatment response. CONCLUSION: These data can help the clinician identify symptoms of lung cancer most reliably associated with objective responses and perceived changes in functional status during chemotherapy. Symptom self-reports could be used by clinicians to monitor patient status and possibly inform treatment modification.

Original languageEnglish (US)
Pages (from-to)51-58
Number of pages8
JournalClinical Lung Cancer
Volume9
Issue number1
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Lung Neoplasms
Drug Therapy
Confusion
Neoplasms
Cough
Weight Loss
Respiration
Pain
Appetite
Therapeutics
Telephone
Non-Small Cell Lung Carcinoma
Dyspnea
Self Report
Nausea
Fatigue
Disease Progression
Thorax

Keywords

  • Disease progression
  • Functional status
  • Non-small-cell lung cancer
  • Patient-reported outcome
  • Treatment response

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. / Cella, David; Eton, David T; Hensing, Thomas A.; Masters, Gregory A.; Parasuraman, Bhash.

In: Clinical Lung Cancer, Vol. 9, No. 1, 01.2008, p. 51-58.

Research output: Contribution to journalArticle

Cella, David ; Eton, David T ; Hensing, Thomas A. ; Masters, Gregory A. ; Parasuraman, Bhash. / Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. In: Clinical Lung Cancer. 2008 ; Vol. 9, No. 1. pp. 51-58.
@article{77e27bee36214dfab9db87fad0102fa4,
title = "Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer",
abstract = "PURPOSE: Our objective was to identify which symptoms of advanced lung cancer are most likely to change with objective tumor measurements (progressions and responses) or changes in performance status (PS). PATIENTS AND METHODS: Eighty patients with advanced non-small-cell lung cancer were studied during the first 12 weeks of chemotherapy. Symptoms were assessed weekly through telephone administration of the Functional Assessment of Cancer Therapy-Lung Symptom lndex-12. Data on PS were collected from patients every 3 weeks. Symptom reports were mapped onto clinical events (progression or response as determined by clinicians) and PS assessments. RESULTS: Disease progression and declining PS were associated with worsening of several symptoms. Pain, shortness of breath, cough, weight loss, and appetite loss worsened most from before to after progression. Patients with an objective response to chemotherapy reported more fatigue and difficulty breathing at response than before response. However, unlike patients who experienced progression, patients responding to chemotherapy never or rarely complained of clinically significant pain, weight loss, cough, chest tightness, nausea, or confusion before, during, or after response. With the exception of bother with side effects of treatment, confusion, and difficulty breathing, symptoms tracked fairly closely over the 12 weeks with changes in PS. Declining PS was associated with considerably more symptom worsening than unchanged or improved PS, independent of treatment response. CONCLUSION: These data can help the clinician identify symptoms of lung cancer most reliably associated with objective responses and perceived changes in functional status during chemotherapy. Symptom self-reports could be used by clinicians to monitor patient status and possibly inform treatment modification.",
keywords = "Disease progression, Functional status, Non-small-cell lung cancer, Patient-reported outcome, Treatment response",
author = "David Cella and Eton, {David T} and Hensing, {Thomas A.} and Masters, {Gregory A.} and Bhash Parasuraman",
year = "2008",
month = "1",
doi = "10.3816/CLC.2008.n.009",
language = "English (US)",
volume = "9",
pages = "51--58",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer

AU - Cella, David

AU - Eton, David T

AU - Hensing, Thomas A.

AU - Masters, Gregory A.

AU - Parasuraman, Bhash

PY - 2008/1

Y1 - 2008/1

N2 - PURPOSE: Our objective was to identify which symptoms of advanced lung cancer are most likely to change with objective tumor measurements (progressions and responses) or changes in performance status (PS). PATIENTS AND METHODS: Eighty patients with advanced non-small-cell lung cancer were studied during the first 12 weeks of chemotherapy. Symptoms were assessed weekly through telephone administration of the Functional Assessment of Cancer Therapy-Lung Symptom lndex-12. Data on PS were collected from patients every 3 weeks. Symptom reports were mapped onto clinical events (progression or response as determined by clinicians) and PS assessments. RESULTS: Disease progression and declining PS were associated with worsening of several symptoms. Pain, shortness of breath, cough, weight loss, and appetite loss worsened most from before to after progression. Patients with an objective response to chemotherapy reported more fatigue and difficulty breathing at response than before response. However, unlike patients who experienced progression, patients responding to chemotherapy never or rarely complained of clinically significant pain, weight loss, cough, chest tightness, nausea, or confusion before, during, or after response. With the exception of bother with side effects of treatment, confusion, and difficulty breathing, symptoms tracked fairly closely over the 12 weeks with changes in PS. Declining PS was associated with considerably more symptom worsening than unchanged or improved PS, independent of treatment response. CONCLUSION: These data can help the clinician identify symptoms of lung cancer most reliably associated with objective responses and perceived changes in functional status during chemotherapy. Symptom self-reports could be used by clinicians to monitor patient status and possibly inform treatment modification.

AB - PURPOSE: Our objective was to identify which symptoms of advanced lung cancer are most likely to change with objective tumor measurements (progressions and responses) or changes in performance status (PS). PATIENTS AND METHODS: Eighty patients with advanced non-small-cell lung cancer were studied during the first 12 weeks of chemotherapy. Symptoms were assessed weekly through telephone administration of the Functional Assessment of Cancer Therapy-Lung Symptom lndex-12. Data on PS were collected from patients every 3 weeks. Symptom reports were mapped onto clinical events (progression or response as determined by clinicians) and PS assessments. RESULTS: Disease progression and declining PS were associated with worsening of several symptoms. Pain, shortness of breath, cough, weight loss, and appetite loss worsened most from before to after progression. Patients with an objective response to chemotherapy reported more fatigue and difficulty breathing at response than before response. However, unlike patients who experienced progression, patients responding to chemotherapy never or rarely complained of clinically significant pain, weight loss, cough, chest tightness, nausea, or confusion before, during, or after response. With the exception of bother with side effects of treatment, confusion, and difficulty breathing, symptoms tracked fairly closely over the 12 weeks with changes in PS. Declining PS was associated with considerably more symptom worsening than unchanged or improved PS, independent of treatment response. CONCLUSION: These data can help the clinician identify symptoms of lung cancer most reliably associated with objective responses and perceived changes in functional status during chemotherapy. Symptom self-reports could be used by clinicians to monitor patient status and possibly inform treatment modification.

KW - Disease progression

KW - Functional status

KW - Non-small-cell lung cancer

KW - Patient-reported outcome

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=39149130337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149130337&partnerID=8YFLogxK

U2 - 10.3816/CLC.2008.n.009

DO - 10.3816/CLC.2008.n.009

M3 - Article

C2 - 18282359

AN - SCOPUS:39149130337

VL - 9

SP - 51

EP - 58

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -